ICU Medical upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded ICU Medical (ICUI) to Strong Buy from Outperform with a price target of $97, down from $205. The firm believes the ...
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting ...
Independent.ie on MSN3d
Clinical trials giant Icon Plc warns investors delay to its Covid vaccine study will hit its revenue for first half of 2025
Icon PLC, the Irish-headquartered clinical research giant, has warned the markets that a large Covid-19 vaccine study it recently told investors about was delayed by its sponsor. In February, CEO ...